More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$35.19B
EPS
-9.15
P/E ratio
--
Price to sales
--
Dividend yield
--
Beta
1.443657
Previous close
$166.87
Today's open
$166.78
Day's range
$161.69 - $167.99
52 week range
$67.27 - $224.31
show more
CEO
Mark A. Goldsmith
Employees
883
Headquarters
Redwood City, CA
Exchange
Nasdaq Global Select
Shares outstanding
216292323
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Revolution Medicines Wins EU Nod for Rasonque in Pancreatic Cancer
RVMD secures European Commission approval for Rasonque in metastatic pancreatic cancer, expanding its reach after a strong U.S. launch.
Zacks Investment Research • Nov 17, 2026

Revolution Medicines, Inc. (RVMD) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Revolution Medicines, Inc. (RVMD) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Seeking Alpha • Nov 16, 2026

European Commission Approves Revolution Medicines' RASONQUE® (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
REDWOOD CITY, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that the European Commission (EC) has approved RASONQUE (daraxonrasib) for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy.1 RASONQUE, given once daily as oral tablets, is approved for adults with metastatic pancreatic adenocarcinoma with or without an identified RAS tumor mutation.
GlobeNewsWire • Nov 16, 2026

Revolution Medicines: RASONQUE Is Off To A Strong Start, But Expectations Are High
Revolution Medicines has transitioned to commercial operations with a strong initial RASONQUE launch, generating $197.6M in five weeks post-FDA approval. RASONQUE's early demand is validated by over 5,000 unique U.S. patients and broad reimbursement, but initial revenues include non-recurring factors and should not be annualized. RVMD's valuation is demanding at 63x forward sales, reflecting high expectations for RASONQUE's expansion and pipeline execution, leaving little room for operational missteps.
Seeking Alpha • Nov 12, 2026

Revolution Medicines, Inc. (RVMD) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript
Revolution Medicines, Inc. ( RVMD ) 3rd Annual Guggenheim Healthcare Innovation Conference November 10, 2026 8:30 AM EST Company Participants Mark Goldsmith - CEO, President & Chairman Presentation Unknown Analyst Kick off this next discussion with Revolution Medicines. With me today, I have Mark Goldsmith, CEO.
Seeking Alpha • Nov 10, 2026

Wall Street Analysts Think Revolution Medicines (RVMD) Could Surge 33.34%: Read This Before Placing a Bet
The consensus price target hints at a 33.3% upside potential for Revolution Medicines (RVMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks Investment Research • Nov 10, 2026

Revolution Medicines' Pancreatic Cancer Drug Nearly Doubled Survival. Is the High-Flying Stock Still a Buy?
Its lead therapy is approved to treat previously treated patients with an advanced form of pancreatic cancer. The young drug company has a revolutionary pipeline of RAS-inhibitor therapies.
The Motley Fool • Nov 8, 2026

Why Royalty Pharma Investors Could Be the Quiet Winners From Revolution Medicines' Groundbreaking Pancreatic Cancer Drug
Revolution Medicines' daraxonrasib has received FDA approval. Royalty Pharma estimates that the drug could produce peak revenues of $11 billion.
The Motley Fool • Nov 8, 2026

What Revolution Medicines (RVMD) Said on Its Q3 Earnings Call
Revolution Medicines NASDAQ: RVMD reported $197.6 million in third-quarter net product revenue from its newly approved pancreatic cancer treatment RASONQUE, reflecting roughly five weeks of U.S. sales and treatment of more than 5,000 commercial patients.
MarketBeat • Nov 5, 2026

Revolution Medicines Q3 Earnings: Stellar Company And Drug, But The Market Knows It
Revolution Medicines delivered $198M in Q3 revenue from RASONQUE's five-week U.S. launch, treating over 5,000 patients post-FDA approval. Despite strong early sales, RVMD's $40B valuation and high expectations temper further upside until sustained commercial traction or pivotal readouts materialize. RASONQUE's clinical data show clear superiority over chemotherapy in pancreatic cancer; expansion into NSCLC and other solid tumors underpins RVMD's multi-asset pipeline thesis.
Seeking Alpha • Nov 5, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Revolution Medicines Inc - Ordinary Shares commission-free¹. Build wealth for the long term using automated trading and transfers.